These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Response of carcinoma of the prostate to withdrawal of flutamide. Collinson MP; Daniel F; Tyrrell CJ; Teasdale C Br J Urol; 1993 Nov; 72(5 Pt 1):662-3. PubMed ID: 10071562 [No Abstract] [Full Text] [Related]
3. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515 [TBL] [Abstract][Full Text] [Related]
6. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Small EJ; Srinivas S Cancer; 1995 Oct; 76(8):1428-34. PubMed ID: 8620419 [TBL] [Abstract][Full Text] [Related]
7. Antiandrogen monotherapy in the management of advanced prostate cancer. Kaisary AV Eur Urol; 1997; 31 Suppl 2():14-9; discussion 24-7. PubMed ID: 9074906 [TBL] [Abstract][Full Text] [Related]
8. Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression. Longmore L; Foley JP; Rozanski TA; Higgins B; Thompson IM South Med J; 1998 Jun; 91(6):573-5. PubMed ID: 9634122 [TBL] [Abstract][Full Text] [Related]
9. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Soloway MS; Schellhammer P; Sharifi R; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G Eur Urol; 1996; 29 Suppl 2():105-9. PubMed ID: 8717471 [TBL] [Abstract][Full Text] [Related]
10. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T; J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218 [TBL] [Abstract][Full Text] [Related]
11. Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma. Figg WD; Kroog G; Duray P; Walther MM; Patronas N; Sartor O; Reed E Cancer; 1997 May; 79(10):1964-8. PubMed ID: 9149024 [TBL] [Abstract][Full Text] [Related]
12. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. Paul R; Breul J Drug Saf; 2000 Nov; 23(5):381-90. PubMed ID: 11085345 [TBL] [Abstract][Full Text] [Related]
13. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Scher HI; Zhang ZF; Nanus D; Kelly WK Urology; 1996 Jan; 47(1A Suppl):61-9. PubMed ID: 8560680 [TBL] [Abstract][Full Text] [Related]
14. Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer. Blackledge GR; Cockshott ID; Furr BJ Eur Urol; 1997; 31 Suppl 2():30-9. PubMed ID: 9074908 [TBL] [Abstract][Full Text] [Related]
15. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group. Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679 [TBL] [Abstract][Full Text] [Related]
16. Re: Characterization of patients with androgen independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. Small EJ J Urol; 1997 Aug; 158(2):552. PubMed ID: 9224356 [No Abstract] [Full Text] [Related]
17. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. Herrada J; Dieringer P; Logothetis CJ J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675 [TBL] [Abstract][Full Text] [Related]
18. Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer. Figg WD; Dawson N; Middleman MN; Brawley O; Lush RM; Senderowicz A; Steinberg SH; Tompkins A; Reed E; Sartor O Acta Oncol; 1996; 35(6):763-5. PubMed ID: 8938230 [No Abstract] [Full Text] [Related]
19. [The antiandrogen withdrawal syndrome: decrease in prostate specific antigen serum levels after withdrawal of antiandrogens]. Hornák M; Bárdos A; Goncalves F Rozhl Chir; 1997 Sep; 76(9):435-7. PubMed ID: 9471771 [TBL] [Abstract][Full Text] [Related]
20. The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer. Barqawi A; Akduman B; Abouelfadel Z; Robischon M; Crawford ED BJU Int; 2003 Nov; 92(7):695-8. PubMed ID: 14616448 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]